CD28-CD57+ T cells from head and neck cancer patients produce high levels of cytotoxic granules and type II interferon but are not senescent.

IF 6.5 2区 医学 Q1 IMMUNOLOGY Oncoimmunology Pub Date : 2024-06-14 eCollection Date: 2024-01-01 DOI:10.1080/2162402X.2024.2367777
Brendan L C Kinney, Brianna Brammer, Vikash Kansal, Connor J Parrish, Haydn T Kissick, Yuan Liu, Nabil F Saba, Zachary S Buchwald, Mark W El-Deiry, Mihir R Patel, Brian J Boyce, Azeem S Kaka, Jennifer H Gross, H Michael Baddour, Amy Y Chen, Nicole C Schmitt
{"title":"CD28-CD57+ T cells from head and neck cancer patients produce high levels of cytotoxic granules and type II interferon but are not senescent.","authors":"Brendan L C Kinney, Brianna Brammer, Vikash Kansal, Connor J Parrish, Haydn T Kissick, Yuan Liu, Nabil F Saba, Zachary S Buchwald, Mark W El-Deiry, Mihir R Patel, Brian J Boyce, Azeem S Kaka, Jennifer H Gross, H Michael Baddour, Amy Y Chen, Nicole C Schmitt","doi":"10.1080/2162402X.2024.2367777","DOIUrl":null,"url":null,"abstract":"<p><p>T lymphocytes expressing CD57 and lacking costimulatory receptors CD27/CD28 have been reported to accumulate with aging, chronic infection, and cancer. These cells are described as senescent, with inability to proliferate but enhanced cytolytic and cytokine-producing capacity. However, robust functional studies on these cells taken directly from cancer patients are lacking. We isolated these T cells and their CD27/28+ counterparts from blood and tumor samples of 50 patients with previously untreated head and neck cancer. Functional studies confirmed that these cells have enhanced ability to degranulate and produce IFN-γ. They also retain the ability to proliferate, thus are not senescent. These data suggest that CD27/28-CD57+ CD8+ T cells are a subset of highly differentiated, CD45RA+ effector memory (T<sub>EMRA</sub>) cells with retained proliferative capacity. Patients with > 34% of these cells among CD8+ T cells in the blood had a higher rate of locoregional disease relapse, suggesting these cells may have prognostic significance.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"13 1","pages":"2367777"},"PeriodicalIF":6.5000,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11181932/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncoimmunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/2162402X.2024.2367777","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

T lymphocytes expressing CD57 and lacking costimulatory receptors CD27/CD28 have been reported to accumulate with aging, chronic infection, and cancer. These cells are described as senescent, with inability to proliferate but enhanced cytolytic and cytokine-producing capacity. However, robust functional studies on these cells taken directly from cancer patients are lacking. We isolated these T cells and their CD27/28+ counterparts from blood and tumor samples of 50 patients with previously untreated head and neck cancer. Functional studies confirmed that these cells have enhanced ability to degranulate and produce IFN-γ. They also retain the ability to proliferate, thus are not senescent. These data suggest that CD27/28-CD57+ CD8+ T cells are a subset of highly differentiated, CD45RA+ effector memory (TEMRA) cells with retained proliferative capacity. Patients with > 34% of these cells among CD8+ T cells in the blood had a higher rate of locoregional disease relapse, suggesting these cells may have prognostic significance.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
头颈癌患者的 CD28-CD57+ T 细胞能产生大量细胞毒性颗粒和 II 型干扰素,但不会衰老。
据报道,表达 CD57 和缺乏成本刺激受体 CD27/CD28 的 T 淋巴细胞会随着衰老、慢性感染和癌症而积累。这些细胞被描述为衰老细胞,不能增殖,但细胞溶解和细胞因子生成能力增强。然而,对这些直接取自癌症患者的细胞缺乏强有力的功能研究。我们从 50 位既往未经治疗的头颈部癌症患者的血液和肿瘤样本中分离出了这些 T 细胞及其 CD27/28+ 对应细胞。功能研究证实,这些细胞具有更强的脱颗粒和产生 IFN-γ 的能力。它们还具有增殖能力,因此不会衰老。这些数据表明,CD27/28-CD57+ CD8+ T细胞是高度分化的CD45RA+效应记忆细胞(TEMRA)的一个亚群,具有保留增殖能力。血液中 CD8+ T 细胞中这些细胞的比例大于 34% 的患者局部区域疾病复发率较高,这表明这些细胞可能对预后有重要意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Oncoimmunology
Oncoimmunology ONCOLOGYIMMUNOLOGY-IMMUNOLOGY
CiteScore
12.50
自引率
2.80%
发文量
276
审稿时长
24 weeks
期刊介绍: OncoImmunology is a dynamic, high-profile, open access journal that comprehensively covers tumor immunology and immunotherapy. As cancer immunotherapy advances, OncoImmunology is committed to publishing top-tier research encompassing all facets of basic and applied tumor immunology. The journal covers a wide range of topics, including: -Basic and translational studies in immunology of both solid and hematological malignancies -Inflammation, innate and acquired immune responses against cancer -Mechanisms of cancer immunoediting and immune evasion -Modern immunotherapies, including immunomodulators, immune checkpoint inhibitors, T-cell, NK-cell, and macrophage engagers, and CAR T cells -Immunological effects of conventional anticancer therapies.
期刊最新文献
Hyperdifferentiated murine melanoma cells promote adaptive anti-tumor immunity but activate the immune checkpoint system. An integral membrane constitutively active heparanase enhances the tumor infiltration capability of NK cells. Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy. Characterisation of the tumour microenvironment and PD-L1 granularity reveals the prognostic value of cancer-associated myofibroblasts in non-invasive bladder cancer. Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumab.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1